Frequency of butyrylcholinesterase gene mutations in individuals with abnormal inhibition numbers: an Italian-population study.

OBJECTIVES More than 30 genetic variants of serum cholinesterase (butyrylcholinesterase, BChE) have been described. Some of them (the atypical and the fluoride-resistant variants) are well known because carriers are prone to develop prolonged apnea following the administration of the muscle relaxant succinylcholine. Genotype characterization is therefore important in order to prevent such episodes. Genetic studies have so far focused on selected individuals or families rather than on the random population. METHODS From a large group of healthy blood donors (n = 2609), we selected all the 58 individuals with low serum cholinesterase activity: among them 28 subjects had abnormal dibucaine and fluoride inhibition numbers. Twenty-five mutations in the coding region of the human cholinesterase gene were analyzed. RESULTS All individuals with abnormal inhibition numbers were homozygotes or double heterozygotes in several mutations. Asp70Gly (Atypical variant) and Ala539Thr (K variant) were the most frequently observed amino acid substitutions. The majority of subjects with low BChE activity but normal dibucaine and fluoride number presented only the K form. We analyzed 106 randomly chosen subjects for K and atypical variants. Carriers of these alleles were at risk of low BChE activity (OR = 9.55, 95%CI, 5.61-16.26 and OR = 30.33, 95%CI, 7.05-130.52 respectively). CONCLUSIONS Data obtained from this study help to better define the etiology of low BChE activity and the role of the rather common K allele. It is the first time that such a large population has been screened for so many mutations. BChE is also implicated in detoxifying cocaine; therefore genetic analysis could be useful in cases of cocaine toxicity in Italian subjects.

[1]  H. Soreq,et al.  Human cholinesterase genes localized by hybridization to chromosomes 3 and 16 , 1987, Human Genetics.

[2]  A. Sastre,et al.  Naturally occurring mutation, Asp70His, in human butyrylcholinesterase , 2002, Annals of clinical biochemistry.

[3]  J. Cashman,et al.  An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient. , 1999, Molecular pharmacology.

[4]  A. Mosca,et al.  Limits to the Use of the Glucose 6-Phosphate Dehydrogenase/6-Phosphogluconate Dehydrogenase Index for the Detection of Glucose 6-Phosphate Dehydrogenase Deficiency , 1998, Clinical chemistry and laboratory medicine.

[5]  M. Maeda,et al.  Identification of a point mutation associated with a silent phenotype of human serum butyrylcholinesterase--a case of familial cholinesterasemia. , 1998, Clinica chimica acta; international journal of clinical chemistry.

[6]  M. Maekawa,et al.  Genetic mutations of butyrylcholine esterase identified from phenotypic abnormalities in Japan. , 1997, Clinical chemistry.

[7]  C. Bartels,et al.  Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene. , 1996, American journal of human genetics.

[8]  M. Maekawa,et al.  Genetic basis of the silent phenotype of serum butyrylcholinesterase in three compound heterozygotes. , 1995, Clinica chimica acta; international journal of clinical chemistry.

[9]  L. Skovgaard,et al.  Identification of human plasma cholinesterase variants in 6,688 individuals using biochemical analysis , 1995, Acta anaesthesiologica Scandinavica.

[10]  C. P. Nogueira,et al.  Identification of two different point mutations associated with the fluoride-resistant phenotype for human butyrylcholinesterase. , 1992, American journal of human genetics.

[11]  C. Bartels,et al.  Structural basis of the butyrylcholinesterase H-variant segregating in two Danish families. , 1992, Pharmacogenetics.

[12]  O. Lockridge,et al.  DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. , 1992, American journal of human genetics.

[13]  C. Bartels,et al.  DNA mutations associated with the human butyrylcholinesterase J-variant. , 1992, American journal of human genetics.

[14]  I. Craig,et al.  Refinement of the localization of human butyrylcholinesterase to chromosome 3q26.1-q26.2 using a PCR-derived probe. , 1991, Genomics.

[15]  O. Lockridge,et al.  The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26. , 1991, Genomics.

[16]  M. Panteghini Methods for serum cholinesterase assay and classification of genetic variants. , 1989, Clinica chimica acta; international journal of clinical chemistry.

[17]  C. P. Nogueira,et al.  Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Whittaker,et al.  Comparison of a commercially available assay system with two reference methods for the determination of plasma cholinesterase variants. , 1983, Clinical chemistry.

[19]  H. Harris,et al.  Differential Inhibition of Human Serum Cholinesterase with Fluoride: Recognition of Two New Phenotypes , 1961, Nature.